Human FGF receptor and β-Klotho binding proteins

US9517264B2 · kind B2 · utility

Assignee

• AMGEN INC. · US

Inventors

• Roger Fachini · Thousand Oaks, US
• Ian Foltz · Burnaby, CA
• Seog Joon Han · Simi Valley, US
• Susie Miki Harris · Newbury Park, US
• Shaw-Fen Sylvia Hu · Thousand Oaks, US
• Chadwick Terence King · North Vancouver, CA
• Yang Li · Santa Clara, US
• Ji Lu · Thousand Oaks, US
• Mark Leo Michaels · Calabasas, US
• Jeonghoon Sun · Thousand Oaks, US

Key dates

• Filing date: Apr 13, 2011
• Grant date: Dec 13, 2016
• Expiry date: Jan 30, 2032

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2319/75
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention provides compositions and methods relating to or derived from antigen binding proteins and antigen binding protein-FGF21 fusions that specifically bind to β-Klotho, or β-Klotho and one or more of FGFR1c, FGFR2c, FGFR3c, and FGFR4. In some embodiments the antigen binding proteins and antigen binding protein-FGF21 fusions induce FGF21-like signaling. In some embodiments, an antigen binding protein or antigen binding protein-FGF21 fusion antigen binding component is a fully human, humanized, or chimeric antibody, binding fragments and derivatives of such antibodies, and polypeptides that specifically bind to β-Klotho, or β-Klotho and one or more of FGFR1c, FGFR2c, FGFR3c, and FGFR4. Other embodiments provide nucleic acids encoding such antigen binding proteins and antigen binding protein-FGF21 fusions, and fragments and derivatives thereof, and polypeptides, cells comprising such polynucleotides, methods of making such antigen binding proteins and antigen binding protein-FGF21 fusions, and fragments and derivatives thereof, and polypeptides, and methods of using such antigen binding proteins and antigen binding protein-FGF21 fusions, fragments and derivatives the…